Aspen Pharmacare Holdings Ltd (APN) - Net Assets
Based on the latest financial reports, Aspen Pharmacare Holdings Ltd (APN) has net assets worth ZAC84.89 Billion ZAC (≈ $45.12 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ZAC135.89 Billion ≈ $72.22 Million USD) and total liabilities (ZAC51.00 Billion ≈ $27.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Aspen Pharmacare Holdings Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ZAC84.89 Billion |
| % of Total Assets | 62.47% |
| Annual Growth Rate | 23.65% |
| 5-Year Change | 29.36% |
| 10-Year Change | 99.75% |
| Growth Volatility | 31.91 |
Aspen Pharmacare Holdings Ltd - Net Assets Trend (2003–2025)
This chart illustrates how Aspen Pharmacare Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Also explore APN asset base for the complete picture of this company's asset base.
Annual Net Assets for Aspen Pharmacare Holdings Ltd (2003–2025)
The table below shows the annual net assets of Aspen Pharmacare Holdings Ltd from 2003 to 2025. For live valuation and market cap data, see how much is Aspen Pharmacare Holdings Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | ZAC84.89 Billion ≈ $45.12 Million |
+0.04% |
| 2024-06-30 | ZAC84.86 Billion ≈ $45.10 Million |
-1.59% |
| 2023-06-30 | ZAC86.24 Billion ≈ $45.83 Million |
+21.56% |
| 2022-06-30 | ZAC70.94 Billion ≈ $37.70 Million |
+8.10% |
| 2021-06-30 | ZAC65.63 Billion ≈ $34.88 Million |
-5.19% |
| 2020-06-30 | ZAC69.22 Billion ≈ $36.79 Million |
+27.68% |
| 2019-06-30 | ZAC54.21 Billion ≈ $28.81 Million |
+8.22% |
| 2018-06-30 | ZAC50.09 Billion ≈ $26.62 Million |
+16.23% |
| 2017-06-30 | ZAC43.10 Billion ≈ $22.91 Million |
+1.41% |
| 2016-06-30 | ZAC42.50 Billion ≈ $22.59 Million |
+24.41% |
| 2015-06-30 | ZAC34.16 Billion ≈ $18.16 Million |
+18.30% |
| 2014-06-30 | ZAC28.88 Billion ≈ $15.35 Million |
+26.66% |
| 2013-06-30 | ZAC22.80 Billion ≈ $12.12 Million |
+31.04% |
| 2012-06-30 | ZAC17.40 Billion ≈ $9.25 Million |
+30.94% |
| 2011-06-30 | ZAC13.29 Billion ≈ $7.06 Million |
+22.06% |
| 2010-06-30 | ZAC10.89 Billion ≈ $5.79 Million |
+155.36% |
| 2009-06-30 | ZAC4.26 Billion ≈ $2.27 Million |
+28.45% |
| 2008-06-30 | ZAC3.32 Billion ≈ $1.76 Million |
+38.89% |
| 2007-06-30 | ZAC2.39 Billion ≈ $1.27 Million |
+38.46% |
| 2006-06-30 | ZAC1.73 Billion ≈ $917.16K |
+55.93% |
| 2005-06-30 | ZAC1.11 Billion ≈ $588.19K |
+3.78% |
| 2004-06-30 | ZAC1.07 Billion ≈ $566.78K |
+34.15% |
| 2003-06-30 | ZAC794.98 Million ≈ $422.49K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aspen Pharmacare Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8947.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ZAC58.09 Billion | 68.43% |
| Common Stock | ZAC1.65 Billion | 1.95% |
| Other Components | ZAC25.15 Billion | 29.62% |
| Total Equity | ZAC84.89 Billion | 100.00% |
Aspen Pharmacare Holdings Ltd Competitors by Market Cap
The table below lists competitors of Aspen Pharmacare Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turkiye Sise ve Cam Fabrikalari AS
IS:SISE
|
$3.28 Billion |
|
Bains Mer Monaco
PA:BAIN
|
$3.29 Billion |
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
$3.29 Billion |
|
Beijing Capital Co Ltd
SHG:600008
|
$3.29 Billion |
|
NCR Atleos Corporation
NASDAQ:NATL
|
$3.28 Billion |
|
Acerinox
MC:ACX
|
$3.28 Billion |
|
Adecco Group AG
F:ADIA
|
$3.28 Billion |
|
Brookdale Senior Living Inc
NYSE:BKD
|
$3.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aspen Pharmacare Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 84,861,000,000 to 84,893,000,000, a change of 32,000,000 (0.0%).
- Net loss of 1,083,000,000 reduced equity.
- Dividend payments of 1,601,000,000 reduced retained earnings.
- Share repurchases of 68,000,000 reduced equity.
- Other comprehensive income decreased equity by 22,445,000,000.
- Other factors increased equity by 25,229,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ZAC-1.08 Billion | -1.28% |
| Dividends Paid | ZAC1.60 Billion | -1.89% |
| Share Repurchases | ZAC68.00 Million | -0.08% |
| Other Comprehensive Income | ZAC-22.45 Billion | -26.44% |
| Other Changes | ZAC25.23 Billion | +29.72% |
| Total Change | ZAC- | 0.04% |
Book Value vs Market Value Analysis
This analysis compares Aspen Pharmacare Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 72.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6385.58x to 72.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-06-30 | ZAC2.18 | ZAC13900.00 | x |
| 2004-06-30 | ZAC2.92 | ZAC13900.00 | x |
| 2005-06-30 | ZAC3.16 | ZAC13900.00 | x |
| 2006-06-30 | ZAC4.60 | ZAC13900.00 | x |
| 2007-06-30 | ZAC6.39 | ZAC13900.00 | x |
| 2008-06-30 | ZAC8.53 | ZAC13900.00 | x |
| 2009-06-30 | ZAC10.93 | ZAC13900.00 | x |
| 2010-06-30 | ZAC25.42 | ZAC13900.00 | x |
| 2011-06-30 | ZAC29.11 | ZAC13900.00 | x |
| 2012-06-30 | ZAC38.20 | ZAC13900.00 | x |
| 2013-06-30 | ZAC49.98 | ZAC13900.00 | x |
| 2014-06-30 | ZAC63.29 | ZAC13900.00 | x |
| 2015-06-30 | ZAC74.78 | ZAC13900.00 | x |
| 2016-06-30 | ZAC93.10 | ZAC13900.00 | x |
| 2017-06-30 | ZAC94.43 | ZAC13900.00 | x |
| 2018-06-30 | ZAC109.70 | ZAC13900.00 | x |
| 2019-06-30 | ZAC118.75 | ZAC13900.00 | x |
| 2020-06-30 | ZAC151.62 | ZAC13900.00 | x |
| 2021-06-30 | ZAC143.76 | ZAC13900.00 | x |
| 2022-06-30 | ZAC156.60 | ZAC13900.00 | x |
| 2023-06-30 | ZAC194.14 | ZAC13900.00 | x |
| 2024-06-30 | ZAC191.04 | ZAC13900.00 | x |
| 2025-06-30 | ZAC191.20 | ZAC13900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aspen Pharmacare Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.50%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.60x
- Recent ROE (-1.28%) is below the historical average (18.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 34.71% | 14.38% | 1.13x | 2.14x | ZAC194.65 Million |
| 2004 | 33.34% | 16.15% | 1.04x | 1.98x | ZAC248.93 Million |
| 2005 | 44.63% | 17.22% | 0.91x | 2.83x | ZAC383.31 Million |
| 2006 | 37.52% | 18.50% | 0.81x | 2.51x | ZAC468.01 Million |
| 2007 | 30.21% | 17.83% | 0.53x | 3.17x | ZAC480.11 Million |
| 2008 | 27.04% | 17.71% | 0.45x | 3.39x | ZAC544.82 Million |
| 2009 | 32.36% | 16.02% | 0.67x | 2.99x | ZAC935.33 Million |
| 2010 | 18.27% | 19.50% | 0.51x | 1.83x | ZAC895.40 Million |
| 2011 | 19.57% | 20.91% | 0.46x | 2.03x | ZAC1.27 Billion |
| 2012 | 16.20% | 18.47% | 0.48x | 1.82x | ZAC1.08 Billion |
| 2013 | 15.44% | 18.23% | 0.43x | 1.99x | ZAC1.24 Billion |
| 2014 | 17.34% | 16.97% | 0.36x | 2.86x | ZAC2.12 Billion |
| 2015 | 15.24% | 14.40% | 0.41x | 2.59x | ZAC1.79 Billion |
| 2016 | 10.12% | 12.08% | 0.34x | 2.45x | ZAC50.00 Million |
| 2017 | 11.83% | 12.38% | 0.35x | 2.70x | ZAC790.00 Million |
| 2018 | 12.00% | 14.11% | 0.32x | 2.65x | ZAC1.00 Billion |
| 2019 | 11.92% | 16.63% | 0.32x | 2.26x | ZAC1.04 Billion |
| 2020 | 6.74% | 12.07% | 0.29x | 1.92x | ZAC-2.26 Billion |
| 2021 | 7.32% | 12.73% | 0.34x | 1.67x | ZAC-1.76 Billion |
| 2022 | 9.15% | 16.81% | 0.35x | 1.57x | ZAC-606.20 Million |
| 2023 | 6.06% | 12.84% | 0.30x | 1.56x | ZAC-3.40 Billion |
| 2024 | 5.19% | 9.85% | 0.32x | 1.64x | ZAC-4.08 Billion |
| 2025 | -1.28% | -2.50% | 0.32x | 1.60x | ZAC-9.57 Billion |
Industry Comparison
This section compares Aspen Pharmacare Holdings Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,624,105,458
- Average return on equity (ROE) among peers: 37.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aspen Pharmacare Holdings Ltd (APN) | ZAC84.89 Billion | 34.71% | 0.60x | $3.28 Billion |
| Adcock Ingram Holdings Limited (AIP) | $3.22 Billion | 23.73% | 0.62x | $583.42 Million |
| Labat Africa Ltd (LAB) | $24.83 Million | 50.68% | 1.53x | $4.39 Million |
About Aspen Pharmacare Holdings Ltd
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more